Pycnogenol can help with heart disease, inflammation, and diabetes



If you find yourself struggling with low energy, menopause or cardiovascular disease, an extract from the French Maritime pine tree shows promise in alleviating these conditions, plus much more. The benefits extend to ailments like diabetes, impotence, asthma, osteoarthritis and swelling in the hands and feet. Additionally, Pycnogenol increases skin elasticity and reduces both oxidative stress and collagen degradation - thereby reducing the effects of aging.

Pycnogenol addresses a wide spectrum of health issues, including the following:

Inflammation -  Inhibiting eicosanoid-generating enzymes, pine bark extract has demonstrated anti-inflammatory and platelet inhibitory effects in vivo.

One study found that 100 mg/day of Pycnogenol taken orally for three months helped decrease anti-inflammatory drug use in 58 percent of the osteoarthritis treatment group. Foot edema (swelling) decreased by 79 percent verses 1 percent in controls.


Pycnogenol also appears to reduce the symptoms of inflammatory bowel disease. Test results published in Phytotherapy Research suggest that pine bark extract "ameliorates ethanol 2,4,6-trinitrobenzene sulfonic acid TNBS-induced inflammation by radical scavenging activity, and may have beneficial effects as a supplement in enteral nutrition for inflammatory bowel disease," according to Ray Sahelian, M.D.

Cardiovascular disease -  A combination of Pycnogenol and Centella asiatica (gotu kola) helped reduce arterial lesions and plaque progression in this study. Furthermore, research published in the journal of Clinical and Applied Thrombosis and Hemostasis showed that pine bark extract minimized edema and improved blood circulation.

Impotence -  Since Pycnogenol encourages nitric oxide production, it supports improved blood vessel dilation, increased blood flow and oxygen to muscles. Several studies have found that pine bark extract significantly improved symptoms of erectile dysfunction and impotence. Supplemental intake of Pycnogenol (60 mg/day), L-arginine (690 mg/day) and aspartic acid (552 mg/day) for eight weeks improved sexual satisfaction and erection hardness. A slight increase in salivary testosterone was also evident in the supplement group.

Menopause -  Findings published in The Journal of Reproductive Medicine noted that 12 weeks of supplementation with Pycnogenol was associated with a noteworthy reduction in perimenopause and menopausal symptoms - including (but not limited to) fatigue, night sweats, hot flashes and insomnia. The double-blind, placebo-controlled trial involved 170 perimenopausal women. The researchers concluded, "This study, applying a relatively low daily dose, allows identification of those climacteric symptoms which respond particularly well to supplementation with Pycnogenol."


   Additional benefits

And there's more. Researchers at Loma Linda University in California found that test subjects, aged 6-18 years old, who took Pycnogenol for three months experienced significant improvement in asthma symptoms compared to the placebo group. In another study, the extract was found to be effective in lowering plasma glucose levels in 77 patients with type 2 diabetes.

Additionally, Pycnogenol improved diabetic microangiopathy, as well as retinopathy - the latter characterized by vascular lesions and hemorrhages that cause vision loss. Treatment with pine bark extract was shown to encourage capillary resistance and curb leakages into the retina.


Source:

"Effect of Low-dose French Maritime Pine Bark Extract on Climacteric Syndrome in 170 Perimenopausal Women - A Randomized, Double-blind, Placebo-controlled Trial" T. Kohama, M. Negami, The Journal of Reproductive Medicine, 2013, Vol. 58, pp. 39-46. Retrieved on July 25, 2014 from: http://europepmc.org/abstract/med/23447917

"Therapuetic efficacy of pycnogenol in experimental inflammatory bowel diseases" Miyako Mochizuki and Noboru Hasegawa, Phytotherapy Research, 2005. Retrieved on July 25, 2014 from: http://onlinelibrary.wiley.com/doi/10.1002/ptr.1611/abstract

"Pycnogenol and Centella Asiatica for saymptomatic atherosclerosis progression" Belcaro G, Dugall M, Hosoi M, Ippolito E, Cesarone M, Luzzi R, Cornelli U, Ledda A, International Angiology: a Journal of the International Union of Angiology, 2014, Vol. 33, pp. 20-26. Retrieved on July 25, 2014 from: http://europepmc.org/abstract/MED/24452082

"Treatment of osteoarthritis with Pycnogenol. The SVOS (San Valentino osteo-arthrosis study). Evaluation of signs, symptoms, physical performance and vascular aspects" G. Belcaro, M. R. Cesarone, S. Errichi, C. Zulli, B. M. Errichi, G. Vinciguerra, A. Ledda, A. Di Renzo, S. Stuard, M. Dugall, L. Pellegrini, S. Errichi, G. Gizzi, E. Ippolito, A. Ricci, M. Cacchio, G. Cipollone, I. Ruffini, F. Fano, M. Hosoi and P. Rohdewald. Phytotherapy Research, 2008. Retrieved on July 25, 2014 from: http://onlinelibrary.wiley.com

"PycnogenolR as an Adjunct in the Management of Childhood Asthma" Benjamin H.S. Lau, M.D., Ph.D., Sharon K. Riesen, M.D., Kim P. Truong, D.O., Esther W. Lau, M.S., R.D., Peter Rohdewald, Ph.D. and Ray A. Barreta, B.S., R.N., Journal of Asthma, 2004, Vol. 41, pp. 825-832. Retrieved on July 25, 2014, from: http://informahealthcare.com




Print Page

Mercury in Vaccines Linked to Autism



Biochemist Brian Hooker, scientific advisor to A Shot of Truth, reveals CDC knew of risks for over a decade

For nearly ten years, Brian Hooker has been requesting documents that are kept under tight wraps by the Centers for Disease Control and Prevention (CDC). His more than 100 Freedom of Information Act (FOIA) requests have resulted in copious evidence that the vaccine preservative Thimerosal, which is still used in the flu shot that is administered to pregnant women and infants, can cause autism and other neurodevelopmental disorders.

Dr. Hooker, a PhD scientist, worked with two members of Congress to craft the letter to the CDC that recently resulted in his obtaining long-awaited data from the CDC, the significance of which is historic. According to Hooker, the data on over 400,000 infants born between 1991 and 1997, which was analyzed by CDC epidemiologist Thomas Verstraeten, MD, “proves unequivocally that in 2000, CDC officials were informed internally of the very high risk of autism, non-organic sleep disorder and speech disorder associated with Thimerosal exposure.”



When the results of the Verstraeten study were first reported outside the CDC in 2005, there was no evidence that anyone but Dr. Verstraeten within the CDC had known of the very high 7.6-fold elevated relative risk of autism from exposure to Thimerosal during infancy. But now, clear evidence exists. A newly -acquired abstract from 1999 titled, “Increased risk of developmental neurologic impairment after high exposure to Thimerosal containing vaccine in first month of life” required the approval of top CDC officials prior to its presentation at the Epidemic Intelligence Service (EIS) conference. Thimerosal, which is 50% mercury by weight, was used in most childhood vaccines and in the RhoGAM® shot for pregnant women prior to the early 2000s.

The CDC maintains there is “no relationship between Thimerosal-containing vaccines and autism rates in children,” even though the data from the CDC’s own Vaccine Safety Datalink (VSD) database shows a very high risk. There are a number of public records to back this up, including this Congressional Record from May 1, 2003. The CDC’s refusal to acknowledge thimerosal’s risks is exemplified by a leaked statement from Dr. Marie McCormick, chair of the CDC/NIH-sponsored Immunization Safety Review at IOM. Regarding vaccination, she said in 2001, “…we are not ever going to come down that it [autism] is a true side effect….” Also of note, the former director of the CDC, which purchases $4 billion worth of vaccines annually, is now president of Merck’s vaccine division.

Dr. Hooker’s fervent hope for the future: “We must ensure that this and other evidence of CDC malfeasance are presented to Congress and the public as quickly as possible. Time is of the essence. Children’s futures are at stake.” A divide within the autism community has led to some activists demanding that compensation to those with vaccine-injury claims be the top priority before Congress. Dr. Hooker maintains that prevention, “protecting our most precious resource – children’s minds,” must come first. “Our elected officials must be informed about government corruption that keeps doctors and patients in the dark about vaccine risks.”

Referring to an organization that has seen its share of controversy this past year, Dr. Hooker remarked, “It is unfortunate that SafeMinds issued a press release on my information, is accepting credit for my work and has not supported a worldwide ban on Thimerosal.”


Brian Hooker, PhD, PE, has 15 years experience in the field of bioengineering and is an associate professor at Simpson University where he specializes in biology and chemistry. His over 50 science and engineering papers have been published in internationally recognized, peer-reviewed journals. Dr. Hooker has a son, aged 16, who developed normally but then regressed into autism after receiving Thimerosal-containing vaccines.

Dr. Brian Hooker’s investigative research is sponsored by the Focus Autism Foundation.

The Focus Autism Foundation is dedicated to providing information to the public that exposes the cause or causes of the autism epidemic and the rise of chronic illnesses – focusing specifically on the role of vaccinations. To learn more, visit focusautisminc.org.

A Shot of Truth is a non-profit 501(c)(3) organization and educational website sponsored by Focus Autism.

AutismOne is a non-profit 501(c)(3) organization that provides education and supports advocacy efforts for children and families touched by an autism diagnosis. To learn more, visit autismone.org.






Print Page
Related Posts Plugin for WordPress, Blogger...